Compare TGTX & MTDR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TGTX | MTDR |
|---|---|---|
| Founded | 1993 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9B | 6.6B |
| IPO Year | 2008 | 2011 |
| Metric | TGTX | MTDR |
|---|---|---|
| Price | $55.60 | $55.41 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 15 |
| Target Price | $49.80 | ★ $63.07 |
| AVG Volume (30 Days) | ★ 2.4M | 2.2M |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 2.38% |
| EPS Growth | ★ 1746.67 | N/A |
| EPS | 0.17 | ★ 2.86 |
| Revenue | $2,785,000.00 | ★ $3,696,277,000.00 |
| Revenue This Year | $49.08 | $7.15 |
| Revenue Next Year | $26.69 | $7.63 |
| P/E Ratio | $326.00 | ★ $19.42 |
| Revenue Growth | N/A | ★ 5.46 |
| 52 Week Low | $26.76 | $37.14 |
| 52 Week High | $59.30 | $66.84 |
| Indicator | TGTX | MTDR |
|---|---|---|
| Relative Strength Index (RSI) | 59.14 | 54.57 |
| Support Level | $51.22 | $52.93 |
| Resistance Level | $58.08 | $57.17 |
| Average True Range (ATR) | 2.24 | 1.65 |
| MACD | 0.74 | 0.36 |
| Stochastic Oscillator | 72.20 | 57.14 |
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
Matador Resources Co is an independent energy company engaged in the exploration, development, production, and acquisition of oil and natural gas resources. The majority of the company's assets are located in the United States, with an emphasis on oil and natural gas shale and other unconventional plays. Along with maintaining a portfolio of oil and natural gas properties, Matador works to identify and develop midstream opportunities that support and enhance its exploration and development business. The Company has two reportable business segments: exploration and production and midstream. The company generates majority of its revenue from the exploration and production segment.